Business Context and Reporting Period
This Form 8-K Current Report was filed by TherapeuticsMD, Inc. on July 6, 2023, covering events occurring on June 29, 2023. The company is a Nevada corporation with its principal executive office in Boca Raton, Florida, and its common stock trades on The Nasdaq Stock Market under the symbol "TXMD."
Key Financial Metrics
The filing reports a specific capital raise event rather than comprehensive period financials.
- Transaction Date: June 29, 2023
- Shares Issued: 312,525 shares of Common Stock
- Price Per Share: $3.6797
- Gross Proceeds: $1,149,998.25
- Investor: Rubric Capital Management LP
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
The primary material change is the execution of a drawdown under a previously disclosed Subscription Agreement dated May 1, 2023. Key developments include:
- Stockholder Approval: On June 26, 2023, stockholders approved the transactions under the Subscription Agreement to satisfy Nasdaq Rules 5635(b) and 5635(d).
- Capital Raise: The company issued and sold 312,525 shares to Rubric Capital Management LP, raising approximately $1.15 million in gross proceeds.
- Regulatory Status: The securities were sold unregistered, relying on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Corporate Governance and Legal Amendments
Effective June 29, 2023, the Board of Directors adopted an amendment to the Company's Bylaws (Fourth Amendment to Bylaws). This amendment renders Nevada's acquisition of controlling interest statutes (NRS 78.378 through 78.3793) inapplicable to the Subscription Agreement and related transactions. The filing does not contain specific management commentary on future guidance, risks, or contingencies beyond the legal exemptions cited for the stock sale.
Investor Verification Checklist
- Verify the total number of shares issued under the Subscription Agreement to date and the remaining capacity (up to 5,000,000 shares total).
- Confirm the dilution impact of the 312,525 shares issued at $3.6797 per share on existing shareholders.
- Review the full text of the Fourth Amendment to Bylaws (Exhibit 3.1) to understand the specific scope of the waiver regarding Nevada controlling interest statutes.
- Check subsequent filings for any additional drawdowns under the Subscription Agreement with Rubric Capital Management LP.